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INTRODUCTION

As the opioid epidemic continues to ravage the United States for a
third decade, 1 communities look for new solutions. For the 200,000 heroinaddicted individuals who pass through correctional facilities each year,
prison may be the opportunity for change. 2
Incarceration pauses access to illicit drugs and presents a chance for
intervention. 3 For individuals with Opioid Use Disorder (“OUD”), the most
effective treatment option involves opioid agonist medication, such as
methadone or buprenorphine. 4 Allowing inmates with OUD to receive
these medications while incarcerated improves outcomes for the individual
inmate and yields public health benefits by reducing costs associated with
poor health, disease transmission, criminality, and recidivism. 5 Despite
these significant benefits to individuals and society, most prisons do not treat
inmates’ OUD with methadone or buprenorphine. 6
This Note examines why most of the United States’ prisons—including
those in Minnesota—resist providing the most effective treatment for OUD.
First, this Note will consider the public policy arguments for and against this
treatment. 7 To begin, OUD will be defined, and its prevalence among
incarcerated individuals in the U.S. will be examined. 8 Next, the best
practices for treating OUD will be detailed, focusing on methadone. 9 The
discussion will then turn to the lack of availability of opioid agonist therapy
within prisons. 10 The rationale for limiting opioid agonist therapy in prisons
will be considered, including fear of diversion within prison, the cost of
providing care, philosophical opposition to utilizing medication when

Opioids: Understanding the Opioid Epidemic, CTRS. FOR DISEASE CONTROL &
PREVENTION,
https://www.cdc.gov/drugoverdose/epidemic/index.html#three-waves
[https://perma.cc/CNL2-LLVB]. The Centers for Disease Control and Prevention (“CDC”)
identifies three waves of the opioid epidemic. Id. The first wave started in the 1990s, when
overdose deaths involving prescription opioid pain medications rose, in conjunction with
doctors prescribing these more frequently. Id. The second wave began in 2010, when
overdose deaths involving heroin rapidly increased. Id. The third wave started in 2013, with
a jump in overdose deaths involving synthetic opioids (especially illicitly manufactured
fentanyl). Id.
See Amy Boutwell, Ank Nijhawan, Nickolas Zaller & Josiah Rich, Arrested on Heroin: A
National Opportunity, 3 J. OPIOID MGMT. 328 (Nov. 2007).
Christine Vestal, New Momentum for Treatment Behind Bars, PEW CHARITABLE TRUSTS
(Apr.
4,
2018),
https://www.pewtrusts.org/en/research-andanalysis/blogs/stateline/2018/04/04/new-momentum-for-addiction-treatment-behind-bars
[https://perma.cc/ZV33-HZWQ].
See NAT’L ACADS. OF SCI., ENG’G, & MED., MEDICATIONS FOR OPIOID USE DISORDER
SAVE LIVES 19 (Alan I. Leshner & Michelle Mancher eds., 2019).
Boutwell, supra note 2.
1

2

3

4

5
6
7
8
9

10

Id.
See infra Section II.
Id.
See infra Section III.
See infra Section IV.
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treating substance use disorders, and regulatory difficulties. 11 Each
justification will be challenged. 12
Next, this Note will explore the legal reasoning that supports allowing
methadone treatment for OUD in prison, including the Eighth
Amendment, the American Disabilities Act (“ADA”), and recent case law. 13
Finally, this discussion will narrow its scope to Minnesota’s state prisons and
consider the current practices of the Department of Corrections. 14 After
evaluation of current policy, this Note will offer recommendations for
change. 15
II. DEFINITION AND PREVALENCE OF OPIOID USE
DISORDER
Opioids are “a class of drugs that include the illegal drug heroin,
synthetic opioids such as fentanyl, and pain relievers available legally by
prescription, such as oxycodone[,] . . . hydrocodone[,] . . . and many
others.” 16 Opioids work by attaching to cell receptors “found in the brain,
spinal cord, and other areas of the body,” thus reducing the sending of pain
messages, as well as the physical sensation of pain in the body. 17 Opioids
activate reward centers in the brain. 18 They trigger the release of endorphins,
which stymie one’s perception of pain and enhance one’s feelings of
pleasure, “creating a temporary but powerful sense of well-being.” 19 When
an individual uses opioids over time, the body slows down its production of
endorphins. 20 A dose of opioids produces a less intense euphoria than it
used to. 21 This experience of tolerance—needing more of the drug to feel the
same effect—is part of what drives an opioid user to increase the amount of
opioids consumed. 22
OUD is clinically diagnosed by physicians and other qualified medical
professionals based on the criteria specified in the Diagnostic and Statistical

11
12
13
14
15
16

See infra Section V.
Id.
See infra Section VI.
See infra Section VII.
Id.
Drug Topics: Opioids, NAT’L INST. ON DRUG ABUSE, https://www.drugabuse.gov/drug-

topics/opioids [https://perma.cc/VVQ8-6ADK].
What Are Opioids? WEBMD, https://www.webmd.com/pain-management/opioidsopiates-explained#1 [https://perma.cc/M3R9-GWZE].
How
Opioid
Addiction
Occurs,
MAYOCLINIC
(Feb.
16,
2018),
https://www.mayoclinic.org/diseases-conditions/prescription-drug-abuse/in-depth/howopioid-addiction-occurs/art-20360372 [https://perma.cc/2BTA-TESD].
17

18

19
20
21
22

Id.
Id.
Id.
Id.
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Manual of Mental Disorders (“DSM-5”). 23 Physical dependence on opioids
contributes to the risk of addiction and makes it particularly difficult for an
individual to stop use. 24 When individuals are forced into withdrawal and
experience a period of abstinence, their tolerance to opioids drops, and they
are at an increased risk of overdose if they return to opioid use. 25 This
vulnerability is commonly seen in people recently released from jail or
prison. 26 North Carolina researchers reviewed fifteen years of records and
discovered that in the “first two weeks after being released from prison,
former inmates were [forty] times more likely to die of an opioid overdose
than someone in the general population.” 27
The prevalence of OUD in the United States is staggering. Data from
the 2016 National Survey on Drug Use and Health indicated more than
11.8 million people over age twelve misused opioids in the previous twelve
months. 28 Among those, approximately 2.1 million people met the criteria
for an OUD diagnosis. 29 With such widespread prevalence, opioid
addiction has impacted society as a whole in the form of health care costs,
criminal activity, homelessness, and increased numbers of children in foster
care. 30 Infectious diseases like Hepatitis C and Human Immunodeficiency
Virus (“HIV”) have had a resurgence due to the volume of intravenous
opioid users. 31 According to the Centers for Disease Control and Prevention
(“CDC”), every day 136 people in the United States die from opioid
overdose. 32

AM. PSYCHIATRIC ASS’N, DIAGNOSTIC & STAT. MANUAL OF MENTAL DISORDERS 541 (5th
ed. 2015). The eleven diagnostic criteria for OUD are: longer duration or larger amount of
opioid use than intended, unsuccessful efforts to cut down or quit use, a great deal of time
spent using or recovering from use, cravings, recurrent use causing failure to meet obligations
at home/work/school, continued use despite interpersonal problems caused or worsened by
use, important life activities given up or reduced due to use, use in physically dangerous
situations, continued use despite knowing physical or psychological issues are worsened by
it, tolerance, and withdrawal. Id. Two to three criteria occurring in a twelve-month period
indicate mild OUD; four to five indicate moderate; and six or more indicate severe. Id.
Shabbar Ranapurwala, Meghan Shanahan, Apostolos Alexandridis, Scott Proescholdbell,
Rebecca Naumann, Daniel Edwards Jr. & Stephen Marshall, Opioid Overdose Mortality
Among Former North Carolina Inmates: 2000-2015, AM. J. PUB. HEALTH (Aug. 8, 2018).
23

24

25
26
27

Id.
Id.
Id.

Rebecca Ahrnsbrak, Jonaki Bose, Sarra Hedden, Rachel Lipari & Eunice Park-Lee, Key
Substance Use and Mental Health Indicators in the United States: Results from the 2016
National Survey on Drug Use and Health, SUBSTANCE ABUSE & MENTAL HEALTH SERV.
28

ADMIN.
(2017),
https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR12016/NSDUH-FFR1-2016.htm#sud7 [https://perma.cc/FN5B-CADD].
29

Id.

NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4, at 17.
Id. Intravenous refers to the “injecting” of drugs into the body’s bloodstream by inserting a
needle into a vein. Id.
CTRS. FOR DISEASE CONTROL & PREVENTION, supra note 1.
30
31

32
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III. BEST PRACTICES FOR TREATING OPIOID USE DISORDER

A. Opioid Agonist Therapy as Best Practice
A variety of evidence-based practices exist for treatment of substance
use disorders. 33 Many of these approaches view addiction through a
biopsychosocial framework, acknowledging addiction has biological
influences, psychological factors, and social (environmental) determinants. 34
In response, treating addiction may require a biological strategy, a
psychological strategy, and a social strategy. 35
Evidence-based biological treatment approaches include medication
prescribed to reduce cravings and manage withdrawal symptoms. 36
Psychological approaches include cognitive-behavioral therapy,
motivational enhancement, community reinforcement, and contingency
management. 37 Evidence-based social approaches include therapeutic
communities. 38
Because of the intense physical dependence and overdose risk
inherent to opioid use, treatment involving medication statistically produces
the best patient outcomes. 39 “The prescribed medication operates to
normalize brain chemistry, block the euphoric effects of . . . opioids, relieve
physiological cravings, and normalize body functions without the negative

Evidence-Based Approaches to Drug Addiction Treatment, NAT’L INST. ON DRUG ABUSE,
(June 3, 2020), https://www.drugabuse.gov/download/675/principles-drug-addictiontreatment-research-based-guide-third-edition.pdf?v=74dad603627bab89b93193918330c223
[https://perma.cc/5RXG-UTF5].
Nora Volkow, What Does It Mean When We Call Addiction a Brain Disorder?, NAT’L
INST. ON DRUG ABUSE: NORA’S BLOG (Mar. 23, 2018), https://www.drugabuse.gov/aboutnida/noras-blog/2018/03/what-does-it-mean-when-we-call-addiction-brain-disorder
[https://perma.cc/XX78-TLJW].
33

34

35

See id.

Kaye Miller Temple, What’s MAT Got to Do with It? Medication-Assisted Treatment for
Opioid Use Disorder in Rural America, RURAL MONITOR (Mar. 21, 2018),
https://www.ruralhealthinfo.org/rural-monitor/medication-assisted-treatment/
[https://perma.cc/GTM4-SUMX].

36

37

Principles of Drug Addiction Treatment: A Research-Based Guide, Behavioral Therapies

NAT’L
INST.
ON
DRUG
ABUSE
(Jan.
2018),
https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-researchbased-guide-third-edition/evidence-based-approaches-to-drug-addictiontreatment/behavioral-therapies [https://perma.cc/8WNA-4F2C].

See Therapeutic Communities Research Report: How is Treatment Provided in a
Therapeutic Community? NAT’L INST. ON DRUG ABUSE (July 2015),
38

https://www.drugabuse.gov/publications/research-reports/therapeutic-communities/howtreatment-provided-in-therapeutic-community [https://perma.cc/TS76-F7S9].
Medications for Opioid Use Disorder Improve Patient Outcomes, PEW CHARITABLE
TRUSTS (Dec. 17, 2020), https://www.pewtrusts.org/en/research-and-analysis/factsheets/2020/12/medications-for-opioid-use-disorder-improve-patientoutcomes#:~:text=The%20most%20effective%20treatments%20for,methadone%2C%20bu
prenorphine%2C%20and%20naltrexone [https://perma.cc/H5QC-99Z6].
39
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and euphoric effects of the substance used.” 40 Agonist therapy stabilizes the
body from the highs and lows of euphoria and withdrawal, allowing a person
to achieve some stability and no longer need to participate in the constant
pursuit of opioids, or in activities to support their addiction. 41
Decades of research demonstrate significantly decreased mortality,
decreased overdoses, decreased intravenous drug use, and reduced
incidence of infectious disease (e.g., HIV, Hepatitis C) in individuals on
long-term agonist therapy. 42 Individuals on agonist therapy show reduction
of high-risk behaviors related to HIV transmission, and they experience
improvement in social functioning and quality of life. 43 Notably, opioid
agonist therapy—specifically, methadone—is associated with reduced levels
of criminality for individuals with OUD. 44
The two primary forms of opioid agonist therapy are methadone and
buprenorphine. 45 This paper will focus its discussion on methadone.
Methadone is a Schedule II, long-lasting synthetic opioid used to treat
OUD. 46 It works by diminishing opioid withdrawal symptoms and reducing
the euphoric high one might feel by using an illicit, short-acting opioid (such
as heroin) on top of it. 47 A nurse administers methadone daily to a patient
as part of a federally-approved opioid treatment program (“OTP”), which
provides counseling and ancillary health services in addition to medication,
culminating in a “whole person,” individualized approach. 48 The duration
of treatment varies per patient, but research indicates a patient should be on
40

Medication-Assisted Treatment, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.

(Sept.
16,
2021),
[https://perma.cc/JHN8-LEVX].
41

https://www.samhsa.gov/medication-assisted-treatment

Id.

NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4, at 33–34; Avril Taylor, Jennifer
Champion & Alex Fleming, The Role of Methadone Maintenance in Scottish Prisons:
Prisoners’ Perspectives, INST. FOR APPLIED SOC. & HEALTH RSCH. (Apr. 2006),
http://www.sps.gov.uk/nmsruntime/saveasdialog.aspx?filename=sps_research_report__the_role_of_methadone_maintenance_in_scottish_prisons.doc [https://perma.cc/3SKWFTTL]. In Scotland, researchers observed a correlation between methadone maintenance
therapy and reduction in criminality among males. Id. In England, patients of methadone
programs had “significantly fewer convictions and cautions, and they spent significantly less
time in prison than they had before the start of treatment.” Id.
42

Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and
Health, SUBSTANCE ABUSE AND MENTAL HEALTH SERVS. ADMIN. (2016),

43

https://www.ncbi.nlm.nih.gov/books/NBK424859/ [https://perma.cc/2MFC-H5FW].
See NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4.
Id. at 19.
Id. The United States Drug Enforcement Administration classifies drugs into five distinct
schedules or categories based on the drug’s medical use and its potential for dependency or
abuse. Drug Scheduling, U.S. DRUG ENFORCEMENT ADMIN., https://www.dea.gov/druginformation/drug-scheduling [https://perma.cc/987D-G6HS]. Schedule II is the second
highest category. Id.
44
45
46

47

Id.
Methadone,

SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-relatedconditions/methadone [https://perma.cc/JHN8-LEVX] (June 8, 2021).
48
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methadone treatment for a minimum of one year. 49
Methadone has long been the favored treatment plan for pregnant
women with OUD who are abusing illicit opioids during pregnancy, as it
stabilizes opioid levels in both mother and baby, preventing medical
problems associated with prenatal withdrawal. 50 Methadone has been the
standard of care for pregnant women with OUD since 1998. 51

B. Efficacy of Opioid Agonist Therapy in Prisons
Research on the effectiveness of opioid agonist therapy in prison has
produced compelling results.
Yale School of Medicine conducted a study on the effects of
continuing methadone treatment during incarceration. 52 All 382 male
participants were enrolled and participated in a methadone program prior
to being incarcerated. 53 Once incarcerated, half continued on methadone;
the other half did not. 54
Those who continued methadone during incarceration—thus avoiding
forced opioid withdrawal—were approximately three times less likely to
receive disciplinary tickets. 55 They were also thirty-two times more likely to
visit a community-based methadone program within a day of release. 56
Those who maintained methadone treatment before, during, and after
incarceration were five times less likely to be re-arrested for a felony and ten
times less likely to be charged for a drug offense after release. 57
The few existing prison- or jail-based methadone programs in the
United States report similar outcomes. Rhode Island Department of
Corrections offers medication-assisted treatment, including methadone, to
inmates in its jails and prisons. 58 In the first year of its program, Rhode Island
saw the post-correctional overdose death rate drop by sixty-one percent,
49
50

Id.
Treating Opioid Use Disorder During Pregnancy, NAT’L INST. ON DRUG ABUSE (July

2017),
https://www.drugabuse.gov/publications/treating-opioid-use-disorder-duringpregnancy#:~:text=Methadone%20has%20been%20used%20to%20treat%20pregnant%20w
omen,practice%20for%20opioid%20use%20disorder%20during%20pregnancy.%201
[https://perma.cc/M8FU-SEDL] (citing recommendations made by the American College of
Obstetricians and Gynecologists and the American Society of Addiction Medicine).
51

Id.

Christopher Gardner, Yale Study: Methadone Treatment in Prison Improves Inmates’
Behavior, Likelihood of Staying Clean Post-Release, YALE SCH. MED. (Jan. 23, 2018),

52

https://medicine.yale.edu/news-article/16631/ [https://perma.cc/G7Q8-29M9].
53
54
55
56
57

Id.
Id.
Id.
Id.
Id.

Ronnie Cohen, Pioneering Approach to Addiction in Rhode Island Jails Saves Lives,
REUTERS
(Feb.
26,
2018),
https://www.reuters.com/article/us-health-addictionprisoners/pioneering-approach-to-addiction-in-rhode-island-jails-saves-livesidUSKCN1GA29V [https://perma.cc/CU46-UNWH].
58
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which contributed to an overall twelve percent drop in the overdose death
rate statewide. 59
In New York City, Rikers Island jail also provides opioid agonist
treatment to inmates. 60 A recent study of inmates with OUD at Rikers Island
Jail showed that, after release:
[N]early nine out of ten inmates who were not medicated
relapsed within a month, as opposed to just [two] out of [five]
inmates who were on medication-assisted treatment. The
difference to society between those two numbers—in terms of
health outcomes, reduced crime, and improved employment
stability—is huge. 61
The public health benefits—reduced recidivism, reduced disease
transmission, reduced overdoses and death—mark a clear benefit to
communities. Notably, Canada, Australia, and all European Union member
states have made methadone treatment available in their prisons. 62 However,
the United States lags behind.
IV. AVAILABILITY OF OPIOID AGONIST THERAPY IN U.S.
PRISONS
With such compelling evidence of the efficacy of opioid agonist
therapy, one would assume it is widespread and accessible during
incarceration, particularly in light of the increased overdose risk inmates
with OUD face following release from prison. Unfortunately, this is not the
case.
In the United States, the Federal Bureau of Prisons, as a rule, does not
permit methadone treatment for inmates, with the exception of pregnant

59

Id.

Megan McLemore, Prisons Are Making America’s Drug Problem Worse, POLITICO (Mar.
11, 2015), https://www.politico.com/magazine/story/2015/03/federal-bureau-of-prisonsmedication-assisted-therapy-115998 [https://perma.cc/6QRB-DV9F].
60

61

Id.

Daniel D’Hotman, Jonathan Pugh & Thomas Douglas, The Case Against Forced
Methadone Detox in the U.S. Prisons, 12 PUBLIC HEALTH ETHICS 89–93 (2019); see also
62

Saman Zamani, Marziyeh Farnia, Saman Tavakoli, Mehran Gholizadeh, Mohammed
Nazari, Ali-Akbar Seddighi, Hamidreza Setayesh, Parviz Afshar & Masahiro Kihara, A

Qualitative Inquiry into Methadone Maintenance Treatment for Opioid-Dependent
Prisoners
in
Tehran,
Iran,
INT.
J.
DRUG
POLICY
(May
2010),
https://doi.org/10.1016/j.drugpo.2009.03.001 [https://perma.cc/9EEA-JMQB]. “The rate of
drug injecting in the prison unit was unanimously reported to have decreased drastically since
introducing the [methadone] program.” Id. In addition to the health benefits, data showed
that methadone treatment also had positive effects on the social status of the inmates’
families. Id. Even so, several barriers to expanding methadone services in prisons were
identified, including staff shortages and stigma related to methadone. Id.
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females with OUD. 63 Only a handful of local jails and a few state prisons
allow methadone treatment. 64
Lack of access to methadone and other opioid agonist therapy in
prison presents significant health risks to inmates with OUD—both
immediately, as they face withdrawal, and long-term, as they contend with
increased risk of blood-borne diseases, overdose, and death. When entering
prison, an inmate with OUD may experience opioid withdrawal because he
has used opioids illicitly up until incarceration, and thus is physically
dependent on them. 65 Withdrawal can also occur when a person is receiving
methadone treatment and consumes a daily amount of the prescribed
medication to maintain physical stability and avoid withdrawal, then enters
a prison where methadone is prohibited and abruptly stops receiving this
daily medication. 66
Opioid withdrawal is extremely uncomfortable. Without a medically
supervised taper, patients anecdotally report methadone to be the most
difficult opioid to withdraw from because of its long-acting properties, which
cause the body to metabolize it over an extended period of time. 67
Withdrawal symptoms include extreme cramping, nausea, diarrhea,
vomiting, and sweating. 68 When an inmate experiences the vomiting and
diarrhea associated with opioid withdrawal, it increases the likelihood of
spreading disease among inmates in the prison. 69 The lack of appropriate
withdrawal management in prisons is sometimes believed to result from a
problematic philosophy held by some who work in corrections, that
“painfully withdrawing from drugs in prison might deter individuals from

Sarah N. Lynch, Woman with Opioid Addiction to Get Regular Methadone Treatment in
Prison, REUTERS (June 7, 2019), https://www.reuters.com/article/us-usa-prisons-opioid63

addiction-idUSKCN1T903F [https://perma.cc/4CS4-WHEL] (describing the Bureau of
Prisons’ policy against methadone and how one woman successfully sued to get permission
to continue methadone treatment in prison despite not being pregnant).
McLemore, supra note 60.
Treatment of Opioid Use Disorder in Correctional Settings, AM. SOC’Y OF ADDICTION
MED. (July 15, 2020), https://www.asam.org/advocacy/find-a-policy-statement/view-policystatement/public-policy-statements/2020/07/16/asam-public-policy-statement-on-treatmentof-opioid-use-disorder-in-correctional-settings [https://perma.cc/9TUX-WNQT].
Kate Wheeling, A Case for Methadone in Our Jails, PAC. STANDARD (May 3, 2017),
https://psmag.com/news/a-case-for-methadone-in-jails [https://perma.cc/8D3K-6GBW].
Id. A thirty-four-year-old woman described her withdrawal experience: “I was dying. When
you're on methadone for three years it stays in your bones. Being in jail without it just about
kills you. I mean, the chills, the sweats, the cramps, the leg cramps, the muscle aches [. . .]
I’d rather come off heroin than methadone any day.” Id.
64
65

66

67

68
69

Id.
Id.
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using drugs.” 70 Research refutes that theory. 71
V. PRISONS’ FLAWED RATIONALE FOR DENYING ACCESS TO
METHADONE TREATMENT
Prisons provide several justifications for their refusal to offer
methadone treatment: diversion within the prison, lack of funding for
methadone programs, philosophical opposition to methadone, and
struggles with the regulatory requirements associated with administering
methadone.

A. Diversion Fears
Diversion occurs when a legally prescribed drug is obtained or used
illegally. 72 When a patient gives or sells their prescription drug to someone
else, they divert the drugs.
Concern about diversion of methadone—or any narcotic medication—
in a correctional setting is justified, as it poses a safety and medical risk.
When a team of researchers and clinicians implemented methadone clinic
services within a Rhode Island prison, correctional staff explicitly expressed
such concerns. 73 Staff feared not only diversion, but the loss of control that
diversion would represent. 74
Staff expressed concern about who would be eligible for initiating
treatment. Correctional staff viewed methadone as something
prized by inmates and saw the provision of methadone as a
privilege and not something all inmates deserved. One officer
Id. (detailing how painful withdrawal may result in medical problems and death, not
deterrence and behavioral change). In Macomb County, Michigan, a thirty-two-year-old
David Stojcevski died in his jail cell while under the watch of jail staff. Id. Stojcevski was jailed
when he failed to pay a $772 fine for careless driving. Id. “[Seventeen] days into a [thirty]day sentence, he had lost [fifty] pounds. Too weak to stand up, he spent at least [forty-eight]
hours on the floor of his cell before dying.” Id. His official cause of death was withdrawal.
Id. Stojcevski had been in methadone treatment before he was jailed, and methadone was
not provided during his incarceration. Id. Stojcevski’s family filed a wrongful death suit
against Macomb County that claimed the defendants were “so deliberately indifferent to
David’s mental health and medical needs that [they] . . . monitored, watched and observed
David spend the final [ten] days of his life suffering . . . .” Id.
Id. The article highlights that a 2009 survey of opioid dependent adults in the Journal of
Psychoactive Drugs found this problematic theory to be false. Id. The authors noted that
"rather than avoiding heroin and other drugs while out in the community, many addicts
simply resolve to try to avoid or minimize withdrawal during future incarceration episodes.”
70

71

Id.
Drug Diversion, CTRS.

FOR DISEASE CONTROL & PREVENTION (Nov. 26, 2019),
https://www.cdc.gov/injectionsafety/drugdiversion/index.html
[https://perma.cc/C6G28Y46].
Michelle McKenzie, Amy Nunn, Nickolas Zaller, Alexander Bazazi & Josiah Rich,
72

73

Overcoming Obstacles to Implementing Methadone Maintenance Therapy for Prisoners:
Implications for Policy and Practice, 5 J. OPIOID MGMT. 219, 223 (2009).
Id.
74
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commented, “You really think this methadone project is going to
work? You know, we don't like to give [the prisoners] any drugs.
You know we even charge them for Tylenol, right?” Accustomed
to controlling both rewards and punishments, and viewing
methadone therapy as a reward, wardens saw distribution of
methadone by medical staff as a threat to their control over
inmates. Wardens felt uncomfortable about the potential
diversion of methadone doses to inmates not in methadone
treatment, both because of the possibility that an inmate's safety
might be put at risk and because the “reward” of becoming
intoxicated might be distributed without their control. 75
Correctional settings that provide methadone dosing develop clear
protocols that, when combined with the liquid state of the medication, make
diversion nearly impossible. 76 Methadone treatment programs provide
patients with a liquid form of methadone. 77 The storage, dosage, and
accounting of the medication are all strictly regulated by the federal
government. 78
For example, the Franklin County Jail in Massachusetts has a practice
that prevents diversion. 79 The nurse provides a liquid dose of methadone to
the patients “as correctional officers stand watch. Every five minutes, [the
nurse] checks each mouth with a flashlight. After three checks[,] the men
are taken to a washroom to rinse their mouths, eat a Saltine cracker, rinse
again, and wash their hands.” 80
The National Institutes of Health (“NIH”) drug abuse division asserts
that diversion of methadone is rare in prison settings. 81 The NIH states that
attempts to divert methadone occur at a rate of one percent, but that strict
dosing supervision can successfully prevent diversion. 82
While fears of diversion may prevent prisons from implementing
methadone treatment, the data does not substantiate the concerns. With
appropriate and achievable dosing supervision, diversion of methadone in
75

Id.

Deborah Becker, Franklin County Jail Is the First Jail in the State That’s Also a Licensed
Treatment
Provider,
WBUR
(Nov.
12,
2019),
https://www.wbur.org/commonhealth/2019/11/12/franklin-county-jail-methadone
[https://perma.cc/REY8-UC9Y].
Methadose Oral Concentrate, RXLIST (June 10, 2021), https://www.rxlist.com/methadoseoral-concentrate-drug.htm#indications [https://perma.cc/D4E9-M5TD] (describing the
cherry-flavored or plain sugar-free liquid concentrate that nurses mix with water to create the
dose of liquid methadone that patients orally consume daily when enrolled in a methadone
treatment program).
76

Methadone

77

78
79
80
81

Id.
Id.
Id.
Treating Opioid Addiction in Criminal Justice Settings, NAT’L INST. ON DRUG ABUSE

(Dec. 14, 2017), https://www.drugabuse.gov/publications/treating-opioid-addiction-incriminal-justice-settings [https://perma.cc/8M78-NZUJ].
82

Id.
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a prison setting is exceedingly rare.

B. Cost of Care
One often-cited barrier to providing methadone to prison inmates is
the cost. Due to regulation, Medicaid funds typically cannot be used to cover
a person’s health care costs during incarceration. 83 Medicaid coverage must
be paused or canceled when a person is incarcerated. 84 This means prisons
incur the costs associated with inmate medical needs. In 2015, states spent
$8.1 billion on health care in correctional facilities. 85 The median expense
was $5,720 per inmate. 86 When inmates stay healthy, state budgets benefit. 87
To dispense methadone to prison inmates, a prison has two options:
it can partner with a private local community-based OTP or create its own
certified OTP within the prison. Opening an OTP is a rigorous process
governed by the Code of Federal Regulations. 88 OTPs must be certified and
accredited by the appropriate bodies, licensed in their state of operation,
and registered with the Drug Enforcement Administration (“DEA”). 89 The
process of opening an OTP is complex and time-consuming, and
maintaining compliance with regulations is equally challenging. In
considering whether to contract or develop their own OTP, prisons must
assess both the financial implications as well as the regulatory demands of
each. Regardless of which route prisons take, grant funding is available to
help finance the endeavor.
As the opioid crisis has swelled, so too have grant dollars for programs
aimed at treatment and prevention. The federal government offers
significant grant funding for the implementation and maintenance of
treatment programs in local and state correctional facilities. Medicationassisted treatment, including methadone, is an approved cost under this
Samantha Scotti, Former Inmates Struggle if They Have No Health Coverage After Being
Released, STATE LEGS. MAGAZINE (Sept. 1, 2017), https://www.ncsl.org/bookstore/state83

legislatures-magazine/health-care-in-and-out-of-prisons.aspx
REAZ].
84
85
86
87
88

[https://perma.cc/YU6R-

Id.
Id.
Id.
Id.
Certification of Opioid Treatment Programs (OTPs), SUBSTANCE ABUSE & MENTAL

HEALTH SERVS. ADMIN. (Oct. 7, 2020), https://www.samhsa.gov/medication-assistedtreatment/become-accredited-opioid-treatment-program [https://perma.cc/RJQ5-MZT2].
The Code of Federal Regulations includes a “system to certify and accredit OTPs, allowing
them to administer and dispense [Food and Drug Administration (“FDA”)] approved
[medication-assisted treatment (“MAT”)] medications. In addition, [OUD] patients receiving
MAT medications must also receive counseling and other behavioral therapies to provide
patients with a whole-person approach.” Id. In addition to medication and counseling, OTPs
are required to “provide counseling on the prevention of human autoimmune virus (“HIV”).
[Substance Abuse and Mental Health Services Administration (“SAMHSA”)] recommends
OTPs also screen and educate high-risk patients on other infectious diseases.” Id.
89

Id.
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grant program. 90 “All grants are awarded to State Administering Agencies
(SAA) who must sub-grant these funds to correctional agencies across their
state.” 91
In addition, the U.S. Department of Justice (“DOJ”) provides grants
under the Residential Substance Abuse Treatment for State Prisoners
(“RSAT”) Program. 92 Agencies that apply for RSAT funds must match
twenty-five percent of the grant award. 93
Opioid-specific grant funding is widely available for programs inside
and outside of incarcerated settings. The DOJ and the Department of
Health and Human Services have several initiatives that offer grant
opportunities: “the Comprehensive Opioid Abuse Site-based Program, the
Opioid Affected Youth Initiative, the Rural Communities Opioid Response
Program, SAMHSA’s Tribal Opioid Response Grants and the HEAL
Initiative among others.” 94
When opening its OTP, Franklin County Jail in Massachusetts relied
on a federal grant. 95 SAMHSA awarded Massachusetts a federal State
Opioid Response Grant of $35,879,685 to “support prevention, treatment,
and recovery services.” 96 From that sum, Franklin County Jail received a
$500,000 grant to support the implementation of its methadone program. 97
For agencies that pursue them, funds exist to assist prisons in
implementing and operating methadone treatment programs,
demonstrating that cost is not a necessary barrier to offering such services.

C. Abstinence Theories of Recovery
Opioid agonist therapy entered the spotlight in new ways as the opioid
epidemic continued, gaining attention from supporters and critics alike.
While the science is undisputed and the positive results of methadone
maintenance are well-documented, misconception and stigma persist.
In 2017, a national study showed the public had “low rates of
awareness . . . about the evidence base for medications to treat OUD . . .
.” 98 More than half the survey respondents believed there is no effective
Using Grants to Fund Inmate Healthcare, CORRECTIONS1 (Dec. 19, 2018),
https://www.corrections1.com/issues-correctional-healthcare/articles/using-grants-to-fundinmate-healthcare-qwmrfpC9tvZXgh6w/ [https://perma.cc/86KK-T9CA].
90

91
92
93
94

Id.
Id.
Id.
Id.

Douglas Hook, Six Months After Launching Massachusetts’ First In-House Methadone
Clinic, Franklin County Jail Is Changing the Way Jails Look at Addiction, MASS LIVE (Feb.

95

23,
2020),
https://www.masslive.com/news/2020/02/six-months-after-launchingmassachusetts-first-in-house-methadone-clinic-franklin-county-jail-is-changing-the-way-jailslook-at-addiction.html [https://perma.cc/Y8E9-RCSH].
96
97
98

Id.
Id.

NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4, at 112.

247

248

MITCHELL HAMLINE LAW REVIEW

[Vol. 48:1

treatment available for OUD. 99
Even among professionals, stigma and misconception persist. This can
be dangerous when ill-informed criminal justice professionals are in the
position of making life-changing treatment plan decisions for an individual
with OUD. 100
[C]ritical treatment decisions often occur in the law enforcement
and judicial systems rather than in medical settings. However, no
policies are in place to require that the people making these
decisions have received any education about evidence-based
OUD treatment. Education and training about OUD for court
officers could increase the uptake of medications to treat OUD.
Probation and parole officers also need to be trained on
medications used to treat people with OUD. Many prison
medical directors limit treatment to abstinence-only or
detoxification-only modalities for people with OUD in their
prisons . . . . Implementing methadone treatment in correctional
facilities can be logistically complicated and impeded by stigma
toward the medication among management and staff; however,
those challenges can and should be addressed . . . . 101
The black-and-white thinking that permeates correctional settings does
not easily comport with the methadone treatment model, which challenges
individuals to reconsider what recovery from addiction means. 102
During the implementation of methadone services in a Rhode Island
jail, the clinicians noted how many of the correctional staff believed drug
addiction was a “moral failing” and should be punished, not treated. 103 The
correctional staff viewed abstinence, without medication assistance like
methadone, as the appropriate approach to overcoming addiction. 104
Abstinence is, of course, less difficult to maintain in a secure,
controlled environment, like prison. Correctional staff may see inmates
99
100
101
102

Id.
Id.
Id. at 115–16.
See Alison Knopf, Expanding OTPs into Corrections in Maryland, ADDICTION

TREATMENT FORUM (Apr. 7, 2019), https://atforum.com/2019/04/expanding-otps-intocorrections-maryland/ [https://perma.cc/R7EV-7QTJ]. A Maryland bill proposed having an
OTP in every jail in the state to offer methadone, buprenorphine, and naltrexone. Id. Some
pointed out that the jails could offer naltrexone and buprenorphine without opening an
OTP; methadone is the only one of the three medications that must be dispensed from an
OTP. Id. However, methadone offers better relief of cravings and has a better rate of
treatment retention than either of the other medications. Id. Major barriers were concern
regarding the cost of the medications and operation of the OTPs, and major opposition from
the jails. Id. The correctional staff asserted they “are corrections, people should be
punished.” Id. Medical professionals point out the issue is medical treatment, not
punishment. Id. “[I]t’s just like somebody with diabetes—they should get treatment.” Id.
While addiction experts and doctors supported the bill, the jails themselves did not. Id.
McKenzie et al., supra note 73.
103
104

Id.
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become healthier and improve in their level of functioning, and they assume
this indicates the inmate is no longer addicted. “Once ‘clean,’ many believe
that the legitimate approach in maintaining abstinence after leaving
incarceration is will power [sic], avoiding negative influences, and finding
support . . . .” 105 This assumption demonstrates a gross misunderstanding of
the complex biopsychosocial nature of addiction and underestimates the
difficulties an inmate faces after release.
Studies abroad have questioned why some nations, including the
United States, resist implementation of prison methadone programs. 106
Some point to prison administrators’ discomfort with medicines used to
treat addiction. 107 Other studies question the concept of treatment in prison,
as prisons are not “therapeutic environments,” and it is unrealistic to expect
emulating community-based programming to succeed in a prison-based
setting. 108 Most importantly, “abstinence based approaches remain more
popular than harm reduction ones in the cultural environment of penal
institutions. This means that detox, rather than [methadone] maintenance,
is the more common mode of methadone . . . in prisons.” 109
Prison administrators’ focus on maintaining a secure and drug-free
facility is “often regarded as incongruent” with methadone treatment. 110
Prison staff report difficulty reconciling the two objectives: making prisons
drug-free, while also aiming to help those with drug problems via
methadone treatment. 111
Despite the fact that methadone has been labeled the “gold standard”
of care for OUD by the NIH, the stigma of methadone treatment is so great
it impacts not just patients, but also the professionals who care for them. 112
This phenomenon earned the name “intervention stigma.” 113 “Unlike
‘condition stigmas’ that mark individuals due to diagnosis, intervention
stigma marks patients and health professionals due to involvement with a
medical treatment or other form of intervention.” 114
Addiction treatment professionals who work in methadone programs
experience discrimination and prejudice from other professionals,
“especially abstinent treatment professionals who disagree with the use of

105
106
107
108
109
110
111

Id.

Taylor, et al., supra note 42.

Id.
Id. at 19.
Id.
Id.
Id.

Erin Fanning Madden, Intervention Stigma: How Medication-Assisted Treatment
Patients and Providers, SOC. SCI. & MED. (July 2019),
https://www.sciencedirect.com/science/article/abs/pii/S0277953619302916?via%3Dihub
[https://perma.cc/2VES-GAJB].
112

Marginalizes
113
114

Id.
Id.
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medications to treat [OUD].” 115 This discrimination may be rooted in stigma
toward addiction generally or at methadone treatment in particular. 116
The irony (and tragedy) is that this stigma targets a treatment model
that has the best outcomes for OUD, and this stigma may then prevent
patients—and programs—from pursuing methadone treatment. 117 Prisons’
bias for abstinence-based recovery is not sufficient reason to deny OUD
inmates access to methadone.

D. Regulatory Challenges
The regulatory requirements for methadone programs are
considerable. 118 When Franklin County Jail decided to apply to open a
methadone program, the sheriff reported it took fifty-four weeks and a
ninety-page application to complete the process. 119 While jails or prisons can
apply to open their own programs, like Franklin County did, some medical
professionals advise against it. One physician in the correctional system
notes, “There are some jails that have applied for methadone treatment
program status. More power to them. I have not, nor will I do so. In my
opinion, the headaches of such a program in my jails would far outweigh
the benefits.” 120
The other option is to contract with a private methadone program in
the community. In such an instance, counseling services are provided via
telemedicine or on-site at the prison—whichever method federal regulators
(or approved federal waivers) permit. 121 The community program typically
delivers pre-packaged methadone doses to the prison, or it creates a
Id.
Id.
See After Years of Stigma, the Conversation Around Methadone Has Long Needed
Change, CARF INT’L (Feb. 5, 2019), http://www.carf.org/OTP-methadone-blog/
115
116
117

[https://perma.cc/2FK5-WMCD]. “Methadone is one of the most widely studied substances
in the United States and has been shown to be safe and effective when used as a component
of holistic treatment for opioid use disorder.” Id. Despite this, stigma around methadone
treatment persists. “The way we talk about methadone often does not communicate the
treatment offerings and efficacy of Opioid Treatment Programs. It’s time we update public
perceptions.” Id.
See Jeffrey Keller, Methadone? In a Jail? JAIL MED. (Sept. 18, 2012),
http://www.jailmedicine.com/methadone-in-a-jail/
[https://perma.cc/JXP2-5BUQ].
A
licensed physician cannot independently prescribe methadone to treat a person’s addiction.
Id. Methadone can only be prescribed through a licensed, accredited OTP which has met
numerous rigorous guidelines set by SAMHSA, the DEA, a professional accreditation body
(such as CARF or the Joint Commission), and state regulators. Id. Physicians can, however,
prescribe methadone to treat chronic pain. If they prescribe it to treat addiction, they face
discipline by the DEA for prescribing narcotics for addiction without the proper
accreditation. Id.
Hook, supra note 95.
Keller, supra note 118.
See Shannon Mace, Anne Siegler, KC Wu, Amanda Latimore & Heather Flynn,
118

119
120
121

Medication-Assisted Treatment for Opioid Use Disorder in Jails and Prisons: A Planning
and Implementation Toolkit, NAT’L COUNCIL FOR BEHAV. HEALTH & VITAL STRATEGIES
52–55 (2020).
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medication unit within the prison to prepare and administer doses. 122
Whether administered through a medication unit, received from a
private program and dispensed, or dispensed from a prison-owned and
operated methadone program, the methadone must be meticulously
accounted for and stored. 123 If it is being transported to the prison from a
community-based clinic, only medical employees of the prison should
accept the methadone. 124 It is transported in a locked container, and every
transfer “must be accounted for on paper, similar to ‘chain-of-evidence’
documentation.” 125 The jail must store the methadone in a double-locked,
secure area, as required for storage of Schedule II narcotics, per the DEA. 126
These regulatory requirements can be cumbersome and inconvenient
but are not insurmountable in a prison setting. With appropriate policies
and procedures in place, and with appropriate staff training to guide
adherence, regulations on methadone should not be a barrier to providing
methadone treatment in prison.
VI. THE LEGAL REASONING FOR METHADONE TREATMENT
IN PRISON
When prison administrators actively refuse to consider the
implementation of methadone treatment in prison, they expose themselves
to risk of litigation for violating the rights of inmates. The following section
explores why inmates are legally entitled to methadone treatment in prison
and provides examples of successful litigation pursued with similar
reasoning.

A. Violation of Inmates’ Rights
Prisons violate inmates’ rights in two ways when denying them access
to methadone treatment. They violate the prohibition against cruel and
unusual punishment as defined under the Eighth Amendment of the U.S.
Constitution. 127 In addition, they violate Title II of the ADA, which protects
SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., supra note 88. A “medication
unit” is a facility located in a geographically separate location, away from the licensed
methadone program. Id. At the medication unit, staff employed by the methadone program
can administer medication and collect samples for drug testing. Id. However, program
admission and counseling services cannot be performed at a medication unit. Id.
“Medication units must follow the same rules and guidelines as outlined by SAMHSA and
the state in which they reside, and must apply and renew for certification.” Id. Medication
units are thought to be helpful “for people living in rural areas with limited accessibility” to a
primary methadone clinic. Id. “Even in major cities, medication units can be a valuable
resource” to help improve patient access to a dosing location away from the primary clinic.
122

Id.
123
124
125
126
127

Keller, supra note 118.

Id.
Id.
Id.

U.S. CONST. amend. VIII.
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individuals with disabilities, including inmates of state prisons, from
enduring discrimination by public entities. 128

1. Eighth Amendment
The Eighth Amendment of the U.S. Constitution states that
“[e]xcessive bail shall not be required, nor excessive fines imposed, nor
cruel and unusual punishments inflicted.” 129 Over time, the courts have
considered and refined what qualifies as cruel and unusual punishment.
In Estelle v. Gamble, state prison inmate J.W. Gamble injured his
back when a bale of cotton fell on him during a prison labor assignment. 130
For the three months following his injury, Gamble complained to prison
staff about back and chest pain. 131 He refused to work, causing prison staff
to put him in administrative segregation. 132 He received medical attention,
though none sufficient to address his pain, and was ultimately treated for an
irregular heartbeat. 133 Gamble sued, arguing that the prison committed
medical malpractice by failing to provide him appropriate medical care and
this amounted to cruel and unusual punishment. 134
The U.S. Supreme Court did not side with Gamble. It determined that
the prison’s failure to provide Gamble appropriate care was a matter for
medical judgment. 135 Though Gamble lost his case, the Court’s ruling served
to establish a clear standard under the Eighth Amendment. The Court held
that a violation of the Eighth Amendment occurs when the prison staff
display “deliberate indifference to [the] serious medical needs of
prisoners.” 136 Such conduct constitutes the “unnecessary and wanton
infliction of pain,” which rises to the level of “cruel and unusual
punishment” under the Eighth Amendment. 137
Estelle established the standard for a prison inmate to bring an Eighth
Amendment claim for cruel and unusual punishment based on deficient
medical care: the inmate must allege an objectively serious medical need
and a prison official’s deliberate indifference to that need. 138
42 U.S.C. § 12132 (1990).
U.S. CONST. amend. VIII.
Estelle v. Gamble, 429 U.S. 97 (1976).
Id. at 101.
Id. at 100.
Id. at 100–01.
Id. at 101.
Id. at 107.
Id. at 104.
Id.
Id.; see also Helling v. McKinney, 509 U.S. 25 (1993). Going beyond what it established
in Estelle, the Court in Helling ruled in favor of a Nevada prison inmate who shared a cell
with a five-pack-a-day smoker and requested to be moved to an environment free of
secondhand smoke. Id. Though the inmate did not have any specific medical condition and
was not seeking medical treatment, the majority wrote that prison officials had “with
deliberate indifference, exposed him to [levels of secondhand smoke] that pose an
128
129
130
131
132
133
134
135
136
137
138
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A medical need may be deemed serious if failure to address it will lead
to a serious risk of harm. 139 Deliberate indifference to the inmate’s medical
need occurs when the prison official realizes a substantial risk of serious
harm to the inmate exists but the official disregards that risk. 140 Access to
effective treatment for OUD is a serious medical need. With access to
effective treatment, such as methadone, the inmate with OUD is at
significantly lower risk of overdose. 141 In addition, methadone treatment
lowers risk of exposure to infectious diseases like HIV and Hepatitis C. 142
And, methadone treatment prevents acute and post-acute withdrawal
symptoms. 143
By not providing access to methadone treatment, prisons show
deliberate indifference to inmates with OUD because of the risk of serious
harm—withdrawal, infectious disease, overdose, and death. 144 Some may
argue that the serious harm is too remote and not immediate enough for
prisons to assume responsibility for providing this care. However, the U.S.
Supreme Court held that a “remedy for unsafe conditions need not await a
tragic event.” 145 Future harm incurred due to an inmate’s current conditions
is reviewable under the Eighth Amendment. 146
Courts observe that the constitutional minimum with respect to health
care has increased over time as contemporary standards change. 147 Whereas
denying inmates access to methadone treatment was not controversial in the
past, the United States is now decades-deep into an opioid epidemic, and
community standards and norms have evolved. The correctional system’s
policy on methadone is directly connected to many of the overdose
deaths. 148
Deliberate indifference occurs when prisons offer less effective but
more easily implemented treatment programs. In the case of OUD,
counseling alone is far less effective than methadone combined with
counseling. 149 Prisons that continue to refuse to offer methadone treatment
to inmates with the serious medical need of effective treatment for OUD

unreasonable risk of serious damage to his future health,” thus his Eighth Amendment claim
was valid. Id. at 35. To win his claim, the inmate would have to prove the risks of secondhand
smoke and prove that it “violates contemporary standards of decency to expose anyone
unwilling to such a risk . . . [He] must show that the risk of which he complains is not one
that today’s society chooses to tolerate.” Id. at 36.
Id. at 33.
Estelle, 429 U.S. at 104–05.
NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4, at 138–39.
139
140
141
142
143
144
145
146
147
148
149

Id.
Id.
Id.

Helling v. McKinney, 509 U.S. 25, 33 (1993).

Id.
Id. at 32–33.
See Gardner, supra note 52.

NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4, at 17–18.
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effectively exhibit deliberate indifference.

2. Americans with Disabilities Act
In addition to a constitutional rights violation, prison inmates with
OUD who are denied methadone treatment may bring a valid claim under
federal civil rights laws, including the ADA, and the Rehabilitation,
Comprehensive Services, and Developmental Disabilities Amendments Act
of 1978 (“Rehabilitation Act”). 150 The ADA and Rehabilitation Act share
similar standards with regard to determining liability. 151 Because of
significant similarities between the laws with regard to disabilities, discussion
here will focus on the ADA.
The ADA protects people with disabilities from discrimination. 152
The ADA defines “disability” as a physical or mental impairment that
substantially limits one or more major life activities. 153 Title II of the ADA
states that “no qualified individual with a disability shall, by reason of such
disability, be excluded from participation in or be denied the benefits of the
services, programs, or activities of a public entity, or be subjected to
discrimination by any such entity.” 154
Under the ADA, people with OUD are deemed individuals with a
disability, provided they are not actively abusing drugs. 155 However, the law
also says that “even current users can’t be denied health care.” 156 Much of
how the ADA applies to these situations is up for interpretation and has yet
to be determined by the courts. Regardless, inmates with OUD have a
qualifying disability, and the prisons charged with their oversight and care
are indeed responsible according to either the ADA or the Rehabilitation
Act.
An inmate with OUD could file a claim under the ADA, employing
either of two arguments: (1) that the prison provided disparate treatment, or
(2) that the prison failed to provide reasonable accommodation or
modification.

Rehabilitation, Comprehensive Services, and Developmental Disabilities Amendments
Act, 29 U.S.C. § 794 (1978).
See 42 U.S.C. § 12132 (1990); see also 29 U.S.C. § 794 (1978).
42 U.S.C. § 12132 (1990).
150

151
152
153
154

Id.
Id.

42 U.S.C. § 12114(a); see also Beth Schwartzapfel, How the Americans with Disabilities
Act Could Change the Way the Nation’s Jails and Prisons Treat Addiction, ABA J. (Feb. 8,

155

2019),
https://www.abajournal.com/news/article/how_the_ada_could_change_jails_prisons_addicti
on_treatment/ [https://perma.cc/7UHX-UWLY]. From the time of its inception, the ADA
has included protection for individuals who are recovering from addictions to drugs or
alcohol. “Yet until recently, the law was rarely invoked on behalf of prisoners taking
methadone. . . . ‘It took this many people dying for people to do what they should have been
doing all along,’ said Sally Friedman, an attorney with the Legal Action Center.” Id.
156

Id.
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a. Disparate Treatment
If the plaintiff argues the prison provided disparate treatment, he is
claiming his disability actually motivated the defendant’s conduct. 157 The
plaintiff bears the initial burden to establish a prima facie case of
discrimination. 158 The defendant then must respond by providing a
legitimate, nondiscriminatory reason for their allegedly discriminatory
conduct. 159 The burden then shifts back to the plaintiff, who must show the
defendant’s legitimate reason is actually just a pretext and not real. 160
Here, the inmate would need to show he was denied adequate
treatment for his OUD by the prison, while other inmates in similar
circumstances were not denied adequate treatment. For example, the
inmate could show he was denied methadone treatment for his OUD, while
other inmates received efficacious treatment and medications for their
conditions.
In response, the prison may argue it has legitimate reasons for
denying inmates access to methadone treatment, such as methadone being
cost-prohibitive, or the facility having fears surrounding diversion of the
drug. However, as discussed earlier, these reasons are not legitimate because
feasible solutions exist. 161 The lack of access to methadone treatment is in
fact discriminatory, and prisons that deny inmates this care demonstrate
disparate treatment of inmates with OUD.

b. Failure to Provide Reasonable Accommodations
Under the ADA, an inmate could claim the prison failed to provide
reasonable accommodations for the inmate with OUD when the prison
denied the inmate methadone treatment. The ADA requires public entities
make reasonable modifications to their policies or rules when the
modification is needed to provide meaningful access to a public service. 162
Limitations to this exist, however, as the ADA states that the entity does not
need to make modifications that would fundamentally alter the nature of
the service or program. 163 Provision of methadone treatment does not
fundamentally alter the nature of the prison, as its outcomes are well aligned
with those of many prisons (rehabilitate inmates, decrease recidivism,
address addiction, etc.). 164 By refusing to provide methadone treatment, the

See Raytheon Co. v. Hernandez, 540 U.S. 44, 52–53 (2003).
See id. at 49–52. Disparate treatment claims under the ADA and Rehabilitation Act are
governed by the McDonnell Douglas burden-shifting analysis used to evaluate claims of
discrimination under Title VII of the Civil Rights Act of 1964. Id.
See id.
See id.
See supra Part V.

157
158

159
160
161
162
163
164

42 U.S.C. § 12132.

Id.
See NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 5, at 138–39.
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prison fails to make reasonable accommodations for inmates with OUD.

B. Successful Legal Actions
In the past five years, cases have emerged showing the Court’s
willingness to consider the application of the Eighth Amendment and ADA
in determining access to methadone in prison. These results prompted
broader conversation in the legal community. 165

1. Pesce v. Coppinger
In Pesce, a U.S. District Court in Massachusetts granted a preliminary
injunction requiring a Massachusetts jail to provide inmate Geoffrey Pesce
with methadone treatment during his incarceration. 166 At the time,
Massachusetts did not have a practice of providing methadone treatment to
inmates. 167
Plaintiff Pesce had a long history of OUD. 168 With the help of
methadone treatment, he was in recovery from OUD since 2016. 169 In July
2018, he was charged with driving with a revoked license, which violated the
terms of his probation. 170 Pesce would serve his resulting sentence in the
Essex County House of Corrections. 171 The facility did not provide or allow
methadone treatment. 172 Pesce requested the court order the jail to allow
him to continue methadone treatment while incarcerated, describing it as a
medically necessary treatment that would diminish his risk of overdose and
death upon release. 173 He sued for an injunction that would allow him to
continue his methadone treatment while incarcerated. 174
Pesce argued that the jail’s policy against methadone treatment
constituted cruel and unusual punishment in violation of the Eighth
Amendment because it demonstrated deliberate indifference to his serious
medical need. 175 The jail’s policy denied him methadone treatment,
repudiating his doctor’s decision that methadone treatment was medically
necessary to treat Pesce’s OUD. 176
Pesce also asserted that the jail’s policy against methadone treatment
violated his rights under the ADA. 177 Pesce asserted he had a qualifying
disability due to his OUD, and the jail’s refusal to administer methadone
deprived him of the benefit of health care programs and such conduct
165
166
167
168
169
170
171
172
173
174
175
176
177

See Schwartzapfel, supra note 157.

Pesce v. Coppinger, 355 F. Supp. 3d 35, 39 (D. Mass. 2018).

Id. at 42.
Id. at 40.
Id. at 41.
Id.
Id. at 41–42.
Id.
Id.
Id. at 43.
Id. at 47–48.
Id.
Id. at 46.
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constituted discrimination on the basis of his disability. 178
Pesce argued that he would suffer irreparable harm if his methadone
treatment was stopped. 179 Before starting methadone, Pesce overdosed
numerous times—at one point, three times within twenty-four hours. 180 His
doctor described him as being very high risk for overdose or death upon his
release from jail if he did not continue methadone treatment. 181
The court ultimately determined that Pesce’s medical needs were of
greater concern than any real or imagined security threats the jail would
experience due to Pesce receiving methadone. 182 While the court validated
the prison’s need for safety and security, it recognized the safeguards in
place—including staff observing Pesce consuming his dose and methadone’s
liquid formulation—made diversion difficult. 183
The Pesce decision marked the first time a federal court in
Massachusetts ruled in favor of providing methadone treatment to prison
inmates. Shortly after the Pesce ruling, the U.S. Court of Appeals for the
First Circuit affirmed a preliminary injunction ordering a Maine jail to
provide an inmate opioid agonist therapy (buprenorphine) to treat OUD. 184
These decisions put pressure on Massachusetts prisons to allow inmates
access to opioid agonist therapy, or to potentially face similar lawsuits.

2. Kortlever v. Whatcom County
As Pesce unfolded in Massachusetts, plaintiffs Gabriel Kortlever and

178
179
180
181
182
183

Id.
Id. at 48.
Id.
Id.
Id. at 49.
Id.

Smith v. Aroostook Cnty., 922 F.3d 41 (1st Cir. 2019). Plaintiff Brenda Smith was
scheduled to serve forty days in the Aroostook County Jail. Id. at 41. The jail informed her
that while incarcerated, she would not receive her twice-daily dose of buprenorphine, which
was prescribed to treat her OUD. Id. at 41–42. Smith sued for injunctive relief. Id. at 42.
The district court balanced potential harms with public interest and found in favor of Smith,
thus issuing a preliminary injunction. Id. Upon appeal, the First Circuit held that the district
court did not abuse its discretion in its assessment and balancing of the issues. Id. The First
Circuit affirmed the district court's grant of a preliminary injunction for Smith, compelling
the jail to provide Smith with her prescribed buprenorphine while she was incarcerated. Id.
184
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Sy Eubanks developed their case in Washington. 185 In Kortlever, 186 a group
of inmates from Whatcom County Jail filed a class action civil rights lawsuit
seeking access to methadone or buprenorphine for jail inmates with
OUD. 187 The lawsuit alleged the Whatcom County Jail only provided
medication-assisted treatment (“MAT”) like methadone or buprenorphine
to pregnant females, while denying MAT to all male and non-pregnant
female inmates with OUD. 188
Kortlever, assisted by the American Civil Liberties Union (“ACLU”)
of Washington, argued this practice of providing MAT to only selected
inmates violated the ADA. 189 He first pointed out that Whatcom County is
in the midst of an opioid epidemic. 190 He went on to argue that OUD is a
disability under the ADA, and MAT is a proven life-saving treatment for
OUD. 191 Kortlever stated that Whatcom County Jail has a policy and
practice of denying MAT to non-pregnant inmates, even though the jail
provides non-pregnant inmates with other clinically appropriate
medications. 192 Kortlever argued that he and other class members suffered
serious and irreparable harm as a result of the jail’s policy of denying
inmates with OUD access to MAT. 193 Despite the serious and irreparable
harm, the jail refused to change its policy and practice regarding MAT. 194
The parties worked together for nearly a year and ultimately reached
a settlement: Whatcom County agreed to provide MAT to inmates with
OUD. 195 This included three options: treatment of opioid withdrawal,
induction onto medication for maintenance as part of treatment, or
continuing MAT the inmate established in the community prior to being
ACLU of Washington Lawsuit: Whatcom County Jail Violating ADA by Refusing
Medication to People with Opioid Use Disorder, ACLU-Wash. (June 7, 2018),
185

https://www.aclu-wa.org/news/aclu-washington-lawsuit-whatcom-county-jail-violating-adarefusing-medication-people-opioid-use [https://perma.cc/KPE3-69XL]. Plaintiff Sy Eubanks
was a forty-six-year-old man with OUD who became addicted to opioids after receiving
prescription painkillers following a surgery. Id. Eventually, he turned to heroin. Id. Eubanks
had success with opioid agonist therapy, utilizing buprenorphine or methadone at different
junctures. Id. Plaintiff Gabriel Kortlever was a twenty-four-year-old man with OUD who
began using heroin at age sixteen. Id. His heroin use contributed to his eventual involvement
with the criminal justice system. Id. He began opioid agonist therapy (buprenorphine) with
the support of his family and probation officer, and found it effective. Id.
Kortlever, v. Whatcom Cty. Wash., No. 2:18-cv-00823, 2018 WL 8809158 (W.D. Wash.
July 23, 2018).
ACLU-WASH., supra note 185.
Compl. at 1, Kortlever v. Whatcom Cty. Wash., No. 2:18-cv-00823, 2018 WL 2763303
(W.D. Wash. June 6, 2018).
Id. at 19.
Id. at 5.
Id. at 8, 20–21.
Id. at 11.
Id. at 13.
Id. at 13–14.
Settlement Agreement, Kortleverv. Whatcom Cty. Wash., No. 2:18-cv-00823 (W.D.
Wash. Apr. 29, 2019), ECF No. 35, see https://www.aclu-wa.org/docs/settlement-agreement1 [https://perma.cc/NGW9-HC85].
186

187
188

189
190
191
192
193
194
195
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incarcerated. 196 In this settlement, Whatcom County agreed to offer only two
MAT options: buprenorphine and naltrexone. 197 Whatcom County did not
agree to provide inmates with methadone maintenance during
incarceration. 198 To address needs of inmates who enter jail on methadone,
this provision was included in the settlement agreement:
If the offender does not wish to transition from methadone to
Suboxone, Subutex or Vivitrol, the Whatcom County Jail will
make reasonable attempts for alternative arrangements to keep
the offender on methadone. Alternative arrangements could
include: transferring the offender to the Skagit County Jail upon
approval of the offender and Skagit County; communication with
prosecution and defense attorneys about the possibility of seeking
in court a less restrictive alternative placement outside of the jail,
or any other means for keeping the offender on methadone that
is approved by the jail. If alternative arrangements cannot be
made, clinically appropriate offenders will be offered the option
of participating in MAT tapering. 199

Kortlever marks the first class action suit of its kind. With widespread
lack of methadone treatment in U.S. jails and prisons, this case may not be
the last of its kind.
VII. MINNESOTA PRISONS’ APPROACH TO OPIOID AGONIST
THERAPY
This Note examined the public policy rationale and legal argument for
allowing methadone treatment in prisons and reviewed cases from the east
and west coasts that helped spur change. This Note now turns its focus to
the Midwest, examining how state prisons in Minnesota treat OUD and
whether opportunity for improvement exists.

A. OUD Population and DOC Treatment Options
Like other states, Minnesota has endured the fatal consequences of the
opioid epidemic—opioid overdoses have increased in Minnesota since
2000. 200 Minnesota’s overdose fatalities show significant racial disparities. In
Minnesota, Native Americans are seven times more likely to die from a drug
overdose as whites, and African Americans are twice as likely to die from a

196
197
198
199

Id. at 6–8.
Id. at 14–24.
Id.
Id. at 19.
Opioids:

Drug Overdose Dashboard, MINN. DEPT. OF HEALTH,
https://www.health.state.mn.us/communities/opioids/opioid-dashboard/index.html
[https://perma.cc/H555-GFMX].
200
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drug overdose as whites. 201
A similar disparity appears in the incarceration rates for drug offenses
in Minnesota. “There is a stark racial disparity in incarceration rates for drug
offenses, especially within the Native American and African American
communities.” 202 By not appropriately treating OUD in the prison
population, the criminal justice system contributes to racial health disparities
and increased risk of recidivism, relapse, and death among Native
Americans and African Americans. 203
Approximately ninety percent of inmates in Minnesota state prisons
have a substance use disorder diagnosis. 204 The Minnesota Department of
Corrections (“DOC”) provides substance use disorder treatment options
during incarceration to all levels of offenders except those in maximum
security. 205 Each year, approximately 6,500 prison inmates are assessed as
needing treatment for a substance use disorder. 206 However, the DOC is
currently funded to provide treatment to about 1,600 inmates each year. 207
None of Minnesota’s DOC facilities currently offer methadone
treatment for the duration of incarceration. 208 Pregnant female inmates
already maintained on methadone who enter a DOC facility are permitted
to continue methadone until delivery of their baby. 209 This policy exception
is presumably in place to avoid putting the fetus at risk of withdrawal, which

201

Id.

Opioids:
Justice-Involved
Populations,
MINN.
DEPT.
OF
HEALTH,
https://www.health.state.mn.us/communities/opioids/mnresponse/justice.html
[https://perma.cc/FZS2-6SYW]. The Minnesota Department of Health’s State Opioid
Oversight Project (“SOOP”) aims to focus on justice-involved populations during its
prevention efforts. Id. This includes individuals who are in prison. Id. Notably, SOOP
acknowledges the racial disparity in incarceration rates for drug offenses and posits these are
“a product of structural racism, social determinants of health, intergenerational trauma, and
other factors that disproportionately impact communities of color.” Id. Native Americans
comprise 1.3% of Minnesota’s general population, yet Minnesota state prisons have between
7 and 22% Native American offenders. Id. African Americans make up 6.2% of Minnesota’s
general population, yet Minnesota state prisons have between 15% and 46% African
American offenders. Id.
202

203
204

Id.
Fact Sheet: Substance Use Disorder Treatment Services in Prison, MINN. DEPT.

OF

HEALTH
(Dec.
2019),
https://mn.gov/doc/assets/Substance%20Use%20Disorder%20Treatment_tcm1089413914.pdf [https://perma.cc/MG5Y-65QF].
205
206

Id.
Id. The DOC reports that offenders can refuse treatment. Id. This may explain why,

despite participants being incarcerated and thus unable to leave, the DOC’s residential
treatment programs had only a 74.9% completion rate in 2018 and a 78.1% completion rate
in 2019. Id. The treatment modality primarily offered to inmates who occupy one of the
1,051 “beds” in a residential program is that of a therapeutic community. Id.
207

Id.

E-mail from Nanette Larson, Dir. of Health Serv., Minn. Dept. of Corr., to author (Oct.
27, 2020, 11:31 AM) (on file with author) [hereinafter “Larson”].

208

209

Id.
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would occur if the prison required pregnant inmates to taper. 210 Per current
policy, males and non-pregnant females at DOC facilities do not have access
to methadone treatment, or any other ongoing opioid agonist therapy. 211
In select circumstances, the DOC offers inmates buprenorphine. If an
inmate shows symptoms of opioid withdrawal, and is objectively assessed to
have physical symptoms severe enough for clinical intervention, the inmate
may receive buprenorphine. 212 This administration of buprenorphine is
solely for symptom relief—not as a maintenance medication. Rarely do
inmates enter a DOC facility experiencing acute withdrawal that would
qualify for buprenorphine, as most inmates complete their acute withdrawal
while in jail awaiting sentencing or transfer to prison. 213
Aside from brief withdrawal management and pregnancy, the other
circumstance in which the DOC may provide buprenorphine is upon an
inmate’s release from prison. 214 For inmates seeking methadone treatment,
no option exists for starting medication before release. Instead, they re-enter
the community at high risk for overdose due to not being stabilized on
NAT’L INST. ON DRUG ABUSE, supra note 38 (discussing risks associated with a mother
experiencing opioid withdrawal during pregnancy).
Larson, supra note 210. The DOC does not currently “offer Methadone to men and
women during incarceration as a form of treatment. With that being said, if a female enters
on methadone, and is pregnant[,] the treatment will be continued.” Id.
Id. The DOC uses the following buprenorphine guidelines:
210

211

212

Id.
Id.
Id.

At time of induction at intake, patients should have evidence of active opioid
withdrawal based upon Clinical Opiate Withdrawal Scale (Score of 6-10 or
higher) or be past acute withdrawal. Induction should generally occur at least 12
hours after the last dose of short acting opiates, including heroin, and 24 hours
after long acting formulations. Patients previously taking illicit methadone
should be at least 36 hours from last dose, but may need longer up to 72 hours.
Intake: Patients in withdrawal (COWS >6-10) can start with 4-8mg SL of
Buprenorphine; if still have COWS>6 in 30 mins, repeat the 4-8 mg. Patients
who respond to the buprenorphine (target is 16 mg) COWS<6 should be able
to remain at the intake facility and continue on 8-16 mg daily. Those who are
not responding should be transferred to the ED for severe withdrawal.
If the patient requires adjuncts such as clonidine and ondansetron requiring 24
hour nursing, the patient should be transferred to the OPH-TCU (or hospital
MCF-SHK).
Additional medications like ondansetron, hydroxyzine, and clonidine shou ld be
given to help with withdrawal symptoms in ALL patients, regardless of whether
an individual is a candidate for buprenorphine.
For patients who have already been on buprenorphine in the community, but
had a lapse in therapy of greater than 2 weeks, and are no longer showing
symptoms/ signs of acute opiate withdrawal, higher doses may be initiated from
above protocol given previous tolerance of medication.

213
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opioid maintenance therapy prior to release. The DOC staff may assist an
inmate with scheduling a post-release appointment at a community-based
methadone clinic. 215
The DOC’s treatment options consist of individual and group therapy
and utilizing a structured curriculum in a therapeutic community setting. 216
For a person with OUD, this is simply not an effective treatment option. 217
Opioid agonist therapy (methadone, buprenorphine) is far more effective. 218

B. Recommendations for Change
Minnesota’s DOC has a unique opportunity to pre-emptively address
the disparate treatment it currently provides to prison inmates with OUD
before inmates take legal action. 219 The DOC could do this by making
methadone treatment available to prison inmates, either by contracting with
a community-based treatment program, or by developing an OTP itself
within the prison. 220
If the DOC contracted with a community-based program, the DOC
could delegate the clinical and medical work to professionals experienced
in developing and running methadone clinics. The DOC could lease the
program space within the prison or on the prison campus. The clinic and
the DOC would be separate entities working in concert. 221 Alternatively, the
DOC could establish methadone services by opening a clinic itself. 222 To do
this, the DOC would benefit from working with an experienced consultant,
as navigating the regulatory requirements of methadone programs can be
215

Id.
Substance Abuse Program: Program Therapist, MINN. DEPT.

OF HEALTH,
https://mn.gov/doc/employment-opportunities/intern-opportunities/internpositions/substance-abuse-program/ [https://perma.cc/2J5V-PXLZ].
Cognitive-Behavioral Therapy which assists clients with identifying, challenging, and
replacing their thinking and beliefs that result in substance abuse and criminal behaviors.
Treatment strategies include education, group therapy, reinforcement, modeling, rehearsal,
and skill building. . . . Structured curriculum, written by MN DOC treatment providers in
partnership with Hazelden Foundation, focuses on treatment readiness, criminal and
addictive thinking, drug education, socialization, co-occurring disorders, relapse prevention,
community reintegration, and victim impact. All components of treatment are designed to
enhance a client's ability to maintain sobriety and conduct himself/herself in a pro-social, lawabiding manner.
216

Id.
See supra Part III.A.
217

NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 4, at 35–39.
See ACLU-WASH., supra note 185. Methadone treatment policies at Whatcom County
Jail were not unlike those currently in place in the DOC. Id. The policies at Whatcom
County Jail resulted in a class action lawsuit.
See supra Part V.D.
See CODAC at the RI Adult Correctional Institutions, CODAC BEHAVIORAL
HEALTHCARE, https://codacinc.org/programs-services/ri-aci/ [https://perma.cc/HHE3Y49D] (demonstrating how CODAC operates methadone clinics within Rhode Island
County Jails).
See Becker, supra note 76 (demonstrating how Franklin County Jail established its own
jail-run methadone clinic).
218
219

220
221
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challenging for the inexperienced.
The DOC has the opportunity to be a leader by approaching
methadone from an evidence-based perspective and promoting induction
and maintenance on methadone during incarceration. Studies show
methadone maintenance should be ongoing throughout the duration of
incarceration, not simply tapered off at the beginning of a prison sentence
or started just prior to someone being released from prison. 223
Minnesota policymakers also bear responsibility for advancing
necessary change. 224 “Policymakers should provide resources and introduce
policy changes to help jails and prisons offer medication and counseling for
OUD and help people transition to community-based care as they leave
incarceration.” 225 Policymakers can request data from state agencies that
show the type of substance use issues in prison and illustrate where needs
lie. 226 Viewing the requested data will help policymakers understand which
“regulatory and programmatic interventions are necessary and help estimate
the needed funding to support jail- and prison-based treatment and re-entry
services.” 227 Once jails and prisons receive funding for new programming,
policymakers should remain supportive throughout program
implementation. 228
Jeffrey A. Wickersham, Ruthanne Marcus, Adeeba Kamarluzaman, Muhammad Muhsin
Zahari & Frederick L. Altice, Implementing Methadone Maintenance Treatment in Prisons
in Malaysia, BULL. OF THE WORLD HEALTH ORG. 124–29 (2013),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605007/ [https://perma.cc/L8J3-WAEU].
Prison-based methadone treatment has great potential for reducing HIV infection rates
among prison inmates and the general population. Id. While implementing a prison-based
methadone program is difficult, methadone continues to be the most efficacious medication
available. Id. Other medications used to treat OUD, such as naltrexone and buprenorphine,
show lower treatment adherence than methadone. Id. Study of Malaysia’s prison-based
methadone program could prove useful for other countries that also struggle with high rates
of OUD and HIV infection among prison inmates. Id.
Intervention should not focus on exclusively using methadone as an intervention
just prior to an inmate’s release from prison. Id. Instead, methadone treatment “should be
leveraged throughout the period of incarceration not only to ensure continuity of care for . .
. participants, but also to ensure adequate methadone dosing before release from prison to
avoid the risky injection of opioids within prison.” Id.
Opioid Use Disorder Treatment in Jails and Prisons, PEW CHARITABLE TRUSTS,
(Apr.
23,
2020),
https://www.pewtrusts.org/en/research-and-analysis/issuebriefs/2020/04/opioid-use-disorder-treatment-in-jails-and-prisons [https://perma.cc/Y6DPPPAW].
223

224

225
226
227

Id.
Id.
Id. “It may also be necessary to fund integrated data systems that facilitate health

information exchange and care continuity across settings.”
Id. Policymakers should:
228

expect prompt program implementation but be mindful that these facilities need
time to develop the necessary medication and counseling program protocols,
calculate demand for services, launch the program, and coordinate with other
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If the DOC does not adapt its approach to OUD treatment, Minnesota
may face legal action much like that seen in Kortlever. 229 Similar to the
Whatcom County Jail, the Minnesota DOC provides medication and
healthcare to its inmates, but methadone treatment is reserved only for
pregnant females with OUD. As demonstrated in Kortlever, this is disparate
treatment under the ADA. The DOC has a responsibility to offer all
inmates with OUD access to life-saving treatment.
VIII. CONCLUSION
Whether spurred forward by research initiatives or reluctantly thrust
into progressive action by court injunctions, some states have had to
reconsider their policies regarding methadone during incarceration. The
policy reasons for doing so are persuasive—reduction in overdoses, deaths,
disease transmission, and recidivism. The legal rationale holds as well, with
plaintiffs filing valid claims under the ADA and Eighth Amendment. As the
opioid epidemic continues, prisons are in a unique position to impact
individuals and society by offering those with OUD methadone treatment
during incarceration. The question remains whether they will.

Id.
229

agencies such as Medicaid and the state’s substance use disorder . . . agency.
Policymakers should request regular updates on persons served and the
program’s successes and challenges.

ACLU-WASH., supra note 185.
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